Rustam N. Heydarov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rustam N. Heydarov has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir M. Mikhailovich
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32 Vavilova St., Moscow, 119991, Russian Federation
9 shared publications - Vladimir Konstantinovich Lyadov
Russian Medical Academy of Continuous Professional Education
5 shared publications - Denis Sergeevich Fedorinov
Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia
4 shared publications - Igor Shashkov
Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences, Moscow 119071, Russia
4 shared publications - Marina A. Lyadova
Moscow City Hospital named after S. S. Yudin, Moscow Healthcare Department; Novokuznetsk State Institute for Advanced Medical Studies – branch of the Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
4 shared publications - Anastasiya A. Kachanova
Russian Medical Academy of Continuous Professional Education
2 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by MDPI AG in Informatics
- Vol. 13 (11) , 184
BioMetaHarmonizer: An Integrated Pipeline for Retrieval, Harmonization and Standardization of NCBI BioSample Metadata for Large-Scale Bacterial Genomic Epidemiological Analysis
Large-scale comparative genomics and antimicrobial resistance surveillance depend on structured, machine-readable sample metadata, yet NCBI BioSample, the primary repository for microbial genomic provenance, contains heterogeneous submitter-supplied metadata despite field-specific validation. Attribute names can vary across submitters, date representations may require normalization, and geographic fields combine country, region, and locality information. Without harmonization and structured extraction, phylogeographic analysis, cross-sector AMR surveillance, and One Health source attribution at the scale of tens to hundreds of thousands of genomes can be labor-intensive and require manual preprocessing that does not scale. We designed BioMetaHarmonizer, an open-source Python package that directly fetches BioSample records from the NCBI Entrez API and transforms them into a standardized 53-column output in CSV, TSV, Excel, Parquet, or JSONL format through a modular harmonization pipeline covering attribute synonym resolution, ISO 8601 date normalization, geospatial parsing with ISO 3166-1 country-code assignment, and automated One Health category inference. Performance of BioMetaHarmonizer was evaluated using 17,573 Bacillus cereus group and 217,226 Klebsiella pneumoniae BioSample records. On a modest cloud virtual machine, the pipeline exhibited end-to-end processing in under 5 and 27 min, respectively, with One Health classification accuracies of 0.9488 and 0.9945. Source code is freely available under the MIT license.
- 2 November 2026
- Published by MDPI AG in Informatics
- Vol. 13 (11) , 184
Open AccessBioMetaHarmonizer: An Integrated Pipeline for Retrieval, Harmonization and Standardization of NCBI BioSample Metadata for Large-Scale Bacterial Genomic Epidemiological Analysis
Large-scale comparative genomics and antimicrobial resistance surveillance depend on structured, machine-readable sample metadata, yet NCBI BioSample, the primary repository for microbial genomic provenance, contains heterogeneous submitter-supplied metadata despite field-specific validation. Attribute names can vary across submitters, date representations may require normalization, and geographic fields combine country, region, and locality information. Without harmonization and structured extraction, phylogeographic analysis, cross-sector AMR surveillance, and One Health source attribution at the scale of tens to hundreds of thousands of genomes can be labor-intensive and require manual preprocessing that does not scale. We designed BioMetaHarmonizer, an open-source Python package that directly fetches BioSample records from the NCBI Entrez API and transforms them into a standardized 53-column output in CSV, TSV, Excel, Parquet, or JSONL format through a modular harmonization pipeline covering attribute synonym resolution, ISO 8601 date normalization, geospatial parsing with ISO 3166-1 country-code assignment, and automated One Health category inference. Performance of BioMetaHarmonizer was evaluated using 17,573 Bacillus cereus group and 217,226 Klebsiella pneumoniae BioSample records. On a modest cloud virtual machine, the pipeline exhibited end-to-end processing in under 5 and 27 min, respectively, with One Health classification accuracies of 0.9488 and 0.9945. Source code is freely available under the MIT license.
- 12 June 2026
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 42 (7)
The genomic landscape of Klebsiella pneumoniae in Russia
Klebsiella pneumoniae is a critical priority pathogen known for its extensive antimicrobial resistance (AMR) and capacity to cause severe infections. The traditional dichotomy between multidrug-resistant (MDR) and hypervirulent strains is rapidly eroding, driving the emergence of highly lethal convergent phenotypes. While global surveillance heavily emphasizes KPC-producing lineages, the specific genomic architecture driving this convergence in the Russian Federation remains insufficiently resolved. In this study, we analyzed population structure represented in a curated dataset 264 K. pneumoniae genomes, comprising 18 newly sequenced clinical isolates and 246 public assemblies from 2015 to 2024, using whole-genome sequencing, pangenome reconstruction, resistome, virulence factors and plasmidome profiling, and CRISPR-Cas typing. Our analysis revealed that high-risk sequence types ST395 (56.1%) and ST147 (8.7%) dominate the regional landscape. Carbapenemase genes were detected in 76.5% of isolates, primarily driven by blaOXA-48 on IncL/M plasmids within ST395 and blaNDM variants in ST147. Crucially, 46.2% of isolates harbored convergent plasmids, predominantly large, mosaic IncFIB/IncHI1B cointegrates, that simultaneously encode hypervirulence determinants like the aerobactin synthesis locus alongside resistance genes including blaNDM-1 and blaCTX-M-15. Additionally, we identified a heavy enrichment of plasmid-borne Type IV-A3 CRISPR-Cas systems in the dominant ST395 clone. The regional dominance of ST395 and ST147, coupled with the extensive horizontal integration of both resistance and virulence, represents a formidable public health threat. These findings underscore the critical need for localized genomic surveillance to effectively monitor evolving convergent pathogens and guide tailored antimicrobial stewardship.
- 12 June 2026
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 42 (7)
The genomic landscape of Klebsiella pneumoniae in Russia
Klebsiella pneumoniae is a critical priority pathogen known for its extensive antimicrobial resistance (AMR) and capacity to cause severe infections. The traditional dichotomy between multidrug-resistant (MDR) and hypervirulent strains is rapidly eroding, driving the emergence of highly lethal convergent phenotypes. While global surveillance heavily emphasizes KPC-producing lineages, the specific genomic architecture driving this convergence in the Russian Federation remains insufficiently resolved. In this study, we analyzed population structure represented in a curated dataset 264 K. pneumoniae genomes, comprising 18 newly sequenced clinical isolates and 246 public assemblies from 2015 to 2024, using whole-genome sequencing, pangenome reconstruction, resistome, virulence factors and plasmidome profiling, and CRISPR-Cas typing. Our analysis revealed that high-risk sequence types ST395 (56.1%) and ST147 (8.7%) dominate the regional landscape. Carbapenemase genes were detected in 76.5% of isolates, primarily driven by blaOXA-48 on IncL/M plasmids within ST395 and blaNDM variants in ST147. Crucially, 46.2% of isolates harbored convergent plasmids, predominantly large, mosaic IncFIB/IncHI1B cointegrates, that simultaneously encode hypervirulence determinants like the aerobactin synthesis locus alongside resistance genes including blaNDM-1 and blaCTX-M-15. Additionally, we identified a heavy enrichment of plasmid-borne Type IV-A3 CRISPR-Cas systems in the dominant ST395 clone. The regional dominance of ST395 and ST147, coupled with the extensive horizontal integration of both resistance and virulence, represents a formidable public health threat. These findings underscore the critical need for localized genomic surveillance to effectively monitor evolving convergent pathogens and guide tailored antimicrobial stewardship.
- Open Access
Towards Personalized Chemotherapy in Gastrointestinal Cancers: Prospective Analysis of Pharmacogenetic Variants in a Russian Cohort
Background/Objectives: Pharmacogenetic variability plays a crucial role in determining both the efficacy and toxicity of chemotherapy for gastrointestinal cancers. However, data on allele frequencies and their clinical relevance in Russian populations remain scarce. Methods: We conducted a prospective observational study of 412 patients with gastrointestinal malignancies between 2020 and 2023. Pharmacogenetic testing was performed prior to the initiation of chemotherapy using real-time allele-specific PCR and microarray hybridization technology. Polymorphisms in the DPYD, UGT1A1, CYP2C8, CYP3A5, GSTP1, ERCC1, XPC, CDA, MTHFR, TYMS, and SLC31A1 genes were analyzed. Results: The frequency of most variants was consistent with those reported in European populations, reflecting the ethnic proximity of the studied cohort. Several clinically relevant variants were identified: DPYD rs2297595 occurred more frequently than in European cohorts, and UGT1A1 rs8175347 was observed at a higher prevalence, underscoring the potential risk of irinotecan-related neutropenia and diarrhea. CYP2C8 rs10509681 was present at frequencies comparable to European populations and is associated with an increased risk of taxane-induced peripheral neuropathy. Other markers (GSTP1, ERCC1, CDA, SLC31A1, MTHFR, TYMS) demonstrated variable associations with chemotherapy efficacy and toxicity, consistent with findings from previous international studies. Conclusions: This study provides the first comprehensive description of pharmacogenetic polymorphisms in a Russian cohort of patients with gastrointestinal cancers. Our findings confirm the clinical importance of DPYD and UGT1A1 testing and highlight additional variants of potential interest.
Open AccessTowards Personalized Chemotherapy in Gastrointestinal Cancers: Prospective Analysis of Pharmacogenetic Variants in a Russian Cohort
Background/Objectives: Pharmacogenetic variability plays a crucial role in determining both the efficacy and toxicity of chemotherapy for gastrointestinal cancers. However, data on allele frequencies and their clinical relevance in Russian populations remain scarce. Methods: We conducted a prospective observational study of 412 patients with gastrointestinal malignancies between 2020 and 2023. Pharmacogenetic testing was performed prior to the initiation of chemotherapy using real-time allele-specific PCR and microarray hybridization technology. Polymorphisms in the DPYD, UGT1A1, CYP2C8, CYP3A5, GSTP1, ERCC1, XPC, CDA, MTHFR, TYMS, and SLC31A1 genes were analyzed. Results: The frequency of most variants was consistent with those reported in European populations, reflecting the ethnic proximity of the studied cohort. Several clinically relevant variants were identified: DPYD rs2297595 occurred more frequently than in European cohorts, and UGT1A1 rs8175347 was observed at a higher prevalence, underscoring the potential risk of irinotecan-related neutropenia and diarrhea. CYP2C8 rs10509681 was present at frequencies comparable to European populations and is associated with an increased risk of taxane-induced peripheral neuropathy. Other markers (GSTP1, ERCC1, CDA, SLC31A1, MTHFR, TYMS) demonstrated variable associations with chemotherapy efficacy and toxicity, consistent with findings from previous international studies. Conclusions: This study provides the first comprehensive description of pharmacogenetic polymorphisms in a Russian cohort of patients with gastrointestinal cancers. Our findings confirm the clinical importance of DPYD and UGT1A1 testing and highlight additional variants of potential interest.
- Open Access
Transcriptome-Wide Analysis of Pituitary and Ectopic Adrenocorticotropic Hormone-Secreting Tumors
Endogenous Cushing’s syndrome (CS) is a rare neuroendocrine disorder characterized by either secondary cortisol increases due to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor (Cushing’s disease (CD)), an ACTH-secreting neuroendocrine tumor (NET) of non-pituitary origin (ectopic ACTH syndrome (EAS)), or by the primarily adrenal autonomous overproduction of cortisol
Open AccessTranscriptome-Wide Analysis of Pituitary and Ectopic Adrenocorticotropic Hormone-Secreting Tumors
Endogenous Cushing’s syndrome (CS) is a rare neuroendocrine disorder characterized by either secondary cortisol increases due to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor (Cushing’s disease (CD)), an ACTH-secreting neuroendocrine tumor (NET) of non-pituitary origin (ectopic ACTH syndrome (EAS)), or by the primarily adrenal autonomous overproduction of cortisol
- Open Access
- 4 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8503
MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy
To reduce severe fluoropyrimidine-related toxicity, pharmacogenetic guidelines recommend a dose reduction for carriers of four high-risk variants in the DPYD gene (*2A, *13, c.2846A>T, HapB3). The polymorphism in the MIR27A gene has been shown to enhance the predictive value of these variants. Our study aimed to explore whether rs895819 in the MIR27A gene modifies the effect of five common DPYD variants: c.1129-5923C>G (rs75017182, HapB3), c.2194G>A (rs1801160, *6), c.1601G>A (rs1801158, *4), c.496A>G (rs2297595), and c.85T>C (rs1801265, *9A). The study included 370 Caucasian patients with gastrointestinal tumors who received fluoropyrimidine-containing chemotherapy. Genotyping was performed using high-resolution melting analysis. The DPYD*6 allele was associated with overall severe toxicity and neutropenia with an increased risk particularly pronounced in patients carrying the MIR27A variant. All carriers of DPYD*6 exhibited an association with asthenia regardless of their MIR27A status. The increased risk of neutropenia in patients with c.496G was only evident in those co-carrying the MIR27A variant. DPYD*4 was also significantly linked to neutropenia risk in co-carriers of the MIR27A variant. Thus, we have demonstrated the predictive value of the *6, *4, and c.496G alleles of the DPYD gene, considering the modifying effect of the MIR27A polymorphism.
- 4 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8503
Open AccessMIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy
To reduce severe fluoropyrimidine-related toxicity, pharmacogenetic guidelines recommend a dose reduction for carriers of four high-risk variants in the DPYD gene (*2A, *13, c.2846A>T, HapB3). The polymorphism in the MIR27A gene has been shown to enhance the predictive value of these variants. Our study aimed to explore whether rs895819 in the MIR27A gene modifies the effect of five common DPYD variants: c.1129-5923C>G (rs75017182, HapB3), c.2194G>A (rs1801160, *6), c.1601G>A (rs1801158, *4), c.496A>G (rs2297595), and c.85T>C (rs1801265, *9A). The study included 370 Caucasian patients with gastrointestinal tumors who received fluoropyrimidine-containing chemotherapy. Genotyping was performed using high-resolution melting analysis. The DPYD*6 allele was associated with overall severe toxicity and neutropenia with an increased risk particularly pronounced in patients carrying the MIR27A variant. All carriers of DPYD*6 exhibited an association with asthenia regardless of their MIR27A status. The increased risk of neutropenia in patients with c.496G was only evident in those co-carrying the MIR27A variant. DPYD*4 was also significantly linked to neutropenia risk in co-carriers of the MIR27A variant. Thus, we have demonstrated the predictive value of the *6, *4, and c.496G alleles of the DPYD gene, considering the modifying effect of the MIR27A polymorphism.
- Open Access
- 22 November 2023
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 100 (5) , 380-390
Molecular-genetic portrait of virulence of Stenotrophomonas maltophilia
Introduction. Stenotrophomonas maltophilia is an opportunistic pathogen that is intrinsically resistant to a wide range of antibiotics. The bacterium is associated with a number of serious diseases and makes a significant contribution to the pathogenesis of polymicrobial infections. S. maltophilia has a wide range of virulence factors, information about which is currently presented in the form of scattered and unconsolidated data. Purposes and objectives: critically analyze and summarize current data regarding the molecular-genetic aspects of S. maltophilia virulence for better understanding of the pathogenesis of infections associated with this pathogen. Materials and methods. An analysis of information from 80 modern literary sources devoted to the study of the virulent properties of S. maltophilia at the molecular-genetic level has been carried out. The analysis focuses on the mechanisms of production of virulence factors and their genetic determinants. Results.The molecular mechanisms of virulence that determine the infectious process caused by S. maltophilia have been analyzed and summarized, including the adhesive function of the surface structures of the bacterial cell (lipopolysaccharides, pili/fimbriae, flagella), the production of extracellular enzymes, the ability to form biofilms on abiotic surfaces and on the tissues of the macroorganism, the functioning of efflux pumps, secretion of small molecules into the external environment by the intercellular information exchange system Quorum Sensing, as well as the influence of iron metabolism on the virulence properties of S. maltophilia. Conclusion. The adaptation mechanisms that allow S. maltophilia to adapt to new habitat niches and survive in the human body and unfavorable environmental conditions have been poorly studied. An analytical review summarizing current information on the molecular-genetic aspects of S. maltophilia virulence will be of interest to clinicians and researchers studying the fundamental mechanisms of virulence.
- 22 November 2023
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 100 (5) , 380-390
Open AccessMolecular-genetic portrait of virulence of Stenotrophomonas maltophilia
Introduction. Stenotrophomonas maltophilia is an opportunistic pathogen that is intrinsically resistant to a wide range of antibiotics. The bacterium is associated with a number of serious diseases and makes a significant contribution to the pathogenesis of polymicrobial infections. S. maltophilia has a wide range of virulence factors, information about which is currently presented in the form of scattered and unconsolidated data. Purposes and objectives: critically analyze and summarize current data regarding the molecular-genetic aspects of S. maltophilia virulence for better understanding of the pathogenesis of infections associated with this pathogen. Materials and methods. An analysis of information from 80 modern literary sources devoted to the study of the virulent properties of S. maltophilia at the molecular-genetic level has been carried out. The analysis focuses on the mechanisms of production of virulence factors and their genetic determinants. Results.The molecular mechanisms of virulence that determine the infectious process caused by S. maltophilia have been analyzed and summarized, including the adhesive function of the surface structures of the bacterial cell (lipopolysaccharides, pili/fimbriae, flagella), the production of extracellular enzymes, the ability to form biofilms on abiotic surfaces and on the tissues of the macroorganism, the functioning of efflux pumps, secretion of small molecules into the external environment by the intercellular information exchange system Quorum Sensing, as well as the influence of iron metabolism on the virulence properties of S. maltophilia. Conclusion. The adaptation mechanisms that allow S. maltophilia to adapt to new habitat niches and survive in the human body and unfavorable environmental conditions have been poorly studied. An analytical review summarizing current information on the molecular-genetic aspects of S. maltophilia virulence will be of interest to clinicians and researchers studying the fundamental mechanisms of virulence.
- Open Access
- 2 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 18,p. 175-184
Pharmacogenetic markers of toxicity of FOLFOX/XELOX chemotherapy in patients with gastrointestinal tumors: a prospective observational study
Introdiction. Systemic chemotherapy (CT) based on oxaliplatin, 5-fluorouracil, capecitabine is the standard of treatment for advanced gastric, colorectal and rectal cancer, which is characterized by frequent development of severe adverse events (AEs). The results of translational studies in the Russian patient population are limited, it is necessary to study pharmacogenetic markers. Aim. To study the frequency of carrying allelic variants of DPYD, GSTP1, MTHFR, XPC, ERCC1, TYMS genes and their association with the development of AEs during palliative treatment with FOLFOX/XELOX.Materials and methods. A total of 166 patients (67 gastric cancer, 99 colorectal cancer) were included in the prospective observational study. All patients underwent pharmacogenetic testing by hybridization analysis on biological microarrays (DPYD (rs2297595 and rs75017182), MTHFR (rs1801133), XPC (rs2228001), TYMS (rs11280056), ERCC1 (rs3212986)) and PCR (GSTP1 (rs1695), ERCC1 (rs11615)) before starting CT. The genotype frequency distribution was analyzed between the groups of patients with and without the development of severe AEs.Results. AEs developed in 97.7% of patients, severe AEs accounting for 54.2%. According to the results of univariate analysis, TC genotype of DPYD gene rs2297595 OR = 3.0 (95% CI 1.2–7.3, p = 0.025), GG genotype of GSTP1 gene rs1695 OR = 2.9 (95% CI 1.02–8.6, p = 0.038) were associated with the development of severe neutropenia. In multivariate analysis TT genotype rs2297595 of the DPYD gene remained the only predictor of severe neutropenia (B ± SE = -1.103 ± 0.503; DI [-2.090; -0.116]; p = 0.028).Conclusions. The results of this study allowed us to identify possible markers of toxicity of FOLFOX/XELOX chemotherapy.
- 2 November 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 18,p. 175-184
Open AccessPharmacogenetic markers of toxicity of FOLFOX/XELOX chemotherapy in patients with gastrointestinal tumors: a prospective observational study
Introdiction. Systemic chemotherapy (CT) based on oxaliplatin, 5-fluorouracil, capecitabine is the standard of treatment for advanced gastric, colorectal and rectal cancer, which is characterized by frequent development of severe adverse events (AEs). The results of translational studies in the Russian patient population are limited, it is necessary to study pharmacogenetic markers. Aim. To study the frequency of carrying allelic variants of DPYD, GSTP1, MTHFR, XPC, ERCC1, TYMS genes and their association with the development of AEs during palliative treatment with FOLFOX/XELOX.Materials and methods. A total of 166 patients (67 gastric cancer, 99 colorectal cancer) were included in the prospective observational study. All patients underwent pharmacogenetic testing by hybridization analysis on biological microarrays (DPYD (rs2297595 and rs75017182), MTHFR (rs1801133), XPC (rs2228001), TYMS (rs11280056), ERCC1 (rs3212986)) and PCR (GSTP1 (rs1695), ERCC1 (rs11615)) before starting CT. The genotype frequency distribution was analyzed between the groups of patients with and without the development of severe AEs.Results. AEs developed in 97.7% of patients, severe AEs accounting for 54.2%. According to the results of univariate analysis, TC genotype of DPYD gene rs2297595 OR = 3.0 (95% CI 1.2–7.3, p = 0.025), GG genotype of GSTP1 gene rs1695 OR = 2.9 (95% CI 1.02–8.6, p = 0.038) were associated with the development of severe neutropenia. In multivariate analysis TT genotype rs2297595 of the DPYD gene remained the only predictor of severe neutropenia (B ± SE = -1.103 ± 0.503; DI [-2.090; -0.116]; p = 0.028).Conclusions. The results of this study allowed us to identify possible markers of toxicity of FOLFOX/XELOX chemotherapy.
- Open Access
- 29 December 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (1) , 77
TYMS 3′-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy that has the worst 5-year survival rate of all of the common malignant tumors. Surgery, chemotherapy, and/or chemoradiation remain the main tactics for PDAC treatment. The efficacy of chemotherapy is often compromised because of the substantial risk of severe toxicities. In our study, we focused on identification of polymorphisms in the genes involved in drug metabolism, DNA repair and replication that are associated with inter-individual differences in drug-induced toxicities. Using the microarray, we genotyped 12 polymorphisms in the DPYD, XPC, GSTP1, MTHFR, ERCC1, UGT1A1, and TYMS genes in 78 PDAC patients treated with FOLFIRINOX. It was found that the TYMS rs11280056 polymorphism (6 bp-deletion in TYMS 3′-UTR) predicted grade 1–2 neurotoxicity (p = 0.0072 and p = 0.0019, according to co-dominant (CDM) and recessive model (RM), respectively). It is the first report on the association between TYMS rs11280056 and peripheral neuropathy. We also found that PDAC patients carrying the GSTP1 rs1695 GG genotype had a decreased risk for grade 3–4 hematological toxicity as compared to those with the AA or AG genotypes (p = 0.032 and p = 0.014, CDM and RM, respectively). Due to relatively high p-values, we consider that the impact of GSTP1 rs1695 requires further investigation in a larger sample size.
- 29 December 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (1) , 77
Open AccessTYMS 3′-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy that has the worst 5-year survival rate of all of the common malignant tumors. Surgery, chemotherapy, and/or chemoradiation remain the main tactics for PDAC treatment. The efficacy of chemotherapy is often compromised because of the substantial risk of severe toxicities. In our study, we focused on identification of polymorphisms in the genes involved in drug metabolism, DNA repair and replication that are associated with inter-individual differences in drug-induced toxicities. Using the microarray, we genotyped 12 polymorphisms in the DPYD, XPC, GSTP1, MTHFR, ERCC1, UGT1A1, and TYMS genes in 78 PDAC patients treated with FOLFIRINOX. It was found that the TYMS rs11280056 polymorphism (6 bp-deletion in TYMS 3′-UTR) predicted grade 1–2 neurotoxicity (p = 0.0072 and p = 0.0019, according to co-dominant (CDM) and recessive model (RM), respectively). It is the first report on the association between TYMS rs11280056 and peripheral neuropathy. We also found that PDAC patients carrying the GSTP1 rs1695 GG genotype had a decreased risk for grade 3–4 hematological toxicity as compared to those with the AA or AG genotypes (p = 0.032 and p = 0.014, CDM and RM, respectively). Due to relatively high p-values, we consider that the impact of GSTP1 rs1695 requires further investigation in a larger sample size.
- Open Access
- 16 August 2021
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 23 (2) , 314-318
Pharmacogenetic markers of chemotherapy toxicity in gastrointestinal tumors: a preliminary analysis
Aim. To assess the association between the carriage of minor allelic variants of 8 genes that encode key enzymes involved in the metabolism of anticancer drugs (DPYD, GSTP1, MTHFR, UGT1A1) and cell repair (XPC, ERCC1, TYMP, NQO1) and the severity of adverse drug events in patients with common gastrointestinal tumors. Tasks. To study the frequency of minor allelic variants of the DPYD, GSTP1, MTHFR, UGT1A1, XPC, ERCC1, TYMP, NQO1 genes; to assess the frequency and severity of adverse drug events of chemotherapy treatment in the study population. Materials and methods. For the period from October 2020 to April 2021, 56 patients (women 29, men 27) with verified malignant tumors of the gastrointestinal tract were included in a prospective clinical study as a part of the RSF grant No. 20-75-10158. The mean age was 62.311.4 years. Colon cancer was detected in 24 patients, tumors of the esophagus and stomach in 19 patients, tumors of pancreas and biliary tract in 13 patients. First-line palliative chemotherapy was given to 27 patients, adjuvant 19 patients, neoadjuvant 10 patients. All patients had not previously received cytotoxic or radiation treatment. Point nucleotide variants of genes DPYD, XPC, GSTP1, MTHFR, ERCC1, UGT1A1, TYMPS, NQO1 were determined by hybridization analysis on biological microchips. Differences in the tolerance of cytotoxic therapy (5-fluorouracil, platinum preparations, irinotecan) depending on the genotype were assessed using Fishers exact test. Results. The average number of chemotherapy courses received was 4.22.6 (112). There was a statistically significant difference in the tolerability of chemotherapy in patients with minor allelic variants of the GSTP1 rs1695 (p=0.03), ERCC1 rs11615 (p=0.01), and UGT1A1 rs8175347 (p=0.003) genes. Conclusion. The use of hybridization analysis on biological microchips to assess allelic variants responsible for the tolerability of cytotoxic therapy is reasonable and requires further prospective assessment.
- 16 August 2021
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 23 (2) , 314-318
Open AccessPharmacogenetic markers of chemotherapy toxicity in gastrointestinal tumors: a preliminary analysis
Aim. To assess the association between the carriage of minor allelic variants of 8 genes that encode key enzymes involved in the metabolism of anticancer drugs (DPYD, GSTP1, MTHFR, UGT1A1) and cell repair (XPC, ERCC1, TYMP, NQO1) and the severity of adverse drug events in patients with common gastrointestinal tumors. Tasks. To study the frequency of minor allelic variants of the DPYD, GSTP1, MTHFR, UGT1A1, XPC, ERCC1, TYMP, NQO1 genes; to assess the frequency and severity of adverse drug events of chemotherapy treatment in the study population. Materials and methods. For the period from October 2020 to April 2021, 56 patients (women 29, men 27) with verified malignant tumors of the gastrointestinal tract were included in a prospective clinical study as a part of the RSF grant No. 20-75-10158. The mean age was 62.311.4 years. Colon cancer was detected in 24 patients, tumors of the esophagus and stomach in 19 patients, tumors of pancreas and biliary tract in 13 patients. First-line palliative chemotherapy was given to 27 patients, adjuvant 19 patients, neoadjuvant 10 patients. All patients had not previously received cytotoxic or radiation treatment. Point nucleotide variants of genes DPYD, XPC, GSTP1, MTHFR, ERCC1, UGT1A1, TYMPS, NQO1 were determined by hybridization analysis on biological microchips. Differences in the tolerance of cytotoxic therapy (5-fluorouracil, platinum preparations, irinotecan) depending on the genotype were assessed using Fishers exact test. Results. The average number of chemotherapy courses received was 4.22.6 (112). There was a statistically significant difference in the tolerability of chemotherapy in patients with minor allelic variants of the GSTP1 rs1695 (p=0.03), ERCC1 rs11615 (p=0.01), and UGT1A1 rs8175347 (p=0.003) genes. Conclusion. The use of hybridization analysis on biological microchips to assess allelic variants responsible for the tolerability of cytotoxic therapy is reasonable and requires further prospective assessment.
- 1 January 2015
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 460 (1) , 4-8
Identification of genetic determinants of influenza A virus resistance to adamantanes and neuraminidase inhibitors using biological microarray
- 1 January 2015
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 460 (1) , 4-8
Identification of genetic determinants of influenza A virus resistance to adamantanes and neuraminidase inhibitors using biological microarray